Eye on the prize, page-13

Prash12 the Neurosurgery product will make Optiscan's reputation but first clinical trials need to be started and successfully completed. Only after that will there be a submission for FDA approval. So that's a way off.
We have been promised an update in June. The market for the CellLive product are researchers using mice.
MR Solutions would surely be expecting to sell hundreds of units. They probably value a cheaper, volume product to fill out their more expensive range of products.
I am hoping their sales team will save this company. But if Optiscan goes bust they look like a company that could buy the IP and run with it.